This protocol addresses synovial sarcoma in adult patients aged 18 years or older. Despite decades of clinical experience, five-year survival rates in this population have remained largely unchanged since the 1980s, with no significant advances in treatment efficacy — making a structured, evidence-based approach to each clinical situation especially important.
For advanced or metastatic disease, management is guided by the extent, location, and resectability of metastatic sites, with surgical approaches applicable in carefully selected patients and systemic anthracycline-based chemotherapy as the standard first-line option for others.
DOI: 10.1016/j.esmoop.2023.101618
Five-year survival rates in adults with SS have plateaued since the 1980s with no advances in treatment efficacy.
In advanced/metastatic STS, metachronous (disease-free interval ≥ 1 year), resectable lung metastases without extrapulmonary disease can be managed with pulmonary surgery alone if complete excision of all lesions is feasible.
Surgery or radiotherapy for the metastatic site(s) without chemotherapy can be considered for fit patients with single organ, limited, and completely resectable/treatable extrapulmonary metastatic disease, while systemic therapy is the preferable option for patients with pulmonary nonresectable disease or extrapulmonary metastatic disease, or short disease-free intervals.
In advanced/metastatic STS, including SS, anthracycline-based chemotherapy is the standard first-line treatment.
View source ↗